Panhypopituitarism without the myth: why multiple deficiencies are not always panhypo

It is worth starting with the definition, because that is where the confusion lives. Panhypopituitarism is the deficiency of multiple anterior pituitary hormones caused by disease of the pituitary itself or of the hypothalamus (Higham et al., 2016). The word that decides is where: the defect is in the central command, in the gland that orchestrates the others, and not in the peripheral glands.

Hence the answer to the question that motivates this text. A patient can have several endocrine deficiencies at the same time, hypothyroidism, low testosterone, low IGF-1, and still not have panhypopituitarism. It is enough that the cause not be central. If each peripheral gland fails on its own, what exists is a set of primary deficiencies, not panhypopituitarism. The count of low hormones may be identical; the origin is opposite.

For the colleague who is going to read the lab panel, the discipline is this: before naming the syndrome, establish the level. And the instrument that establishes the level is not the target gland's hormone, it is the trophic hormone that the pituitary should be sending.

Here is the point the colleague needs to retain. The most common cause of a patient accumulating several hormone deficiencies is not a central lesion, it is the degeneration of function of the glands themselves, a multifactorial process whose dominant driver is aging. Each axis ages in its own way, and the sum gives the impression of pituitary collapse when there is none.

In women, menopause is the purest example of age-related primary endocrine failure: the ovary exhausts its follicles, estradiol falls and FSH and LH rise sharply. It is the biochemical portrait of the primary form, with high trophics, and has nothing pituitary about it. In men, late-onset hypogonadism is more subtle and mixes components: with age testosterone declines and LH tends to rise, a sign that there is a primary testicular component added to the central one (Wu et al., EMAS, 2010). It is a diagnosis that requires sexual symptoms plus confirmed low testosterone, and one that is not treated simply because the number fell with age (Bhasin et al., 2018).

The thyroid follows the same logic: the prevalence of primary hypothyroidism, generally autoimmune, grows with age, with high TSH, the opposite of the central pattern. And the growth hormone axis has an important semantic trap: IGF-1 falls physiologically with age, the so-called somatopause, and this is not GH deficiency in the clinical sense. Confusing the somatopause, which is normal aging, with adult GH deficiency, which is pituitary disease proven by a stimulation test, is one of the errors that most fuels the optimization market.

The practical result is a sixty-year-old patient who brings together low testosterone, a subclinical primary hypothyroidism, an IGF-1 at the lower limit for age and a low vitamin D. Four findings, four distinct mechanisms, none of them central. Calling this set panhypopituitarism is an error of reasoning; the correct term is multiple endocrine deficiencies, of primary and multifactorial cause, with age at the center.

It is worth isolating vitamin D because it frequently enters the conversation by mistake. It is not a pituitary hormone nor an endocrine gland that has failed in the sense of Addison's or hypothyroidism. It is a pro-hormone of nutritional status, which depends on sun, diet, skin and on hydroxylations in the liver and the kidney. Low 25-OH-vitamin D is a common and very frequent nutritional insufficiency, unrelated to pituitary command.

Adding it to the list of failing hormones to suggest panhypopituitarism, or even a polyglandular syndrome, is to mix things of entirely distinct mechanism, prevalence and clinical weight. It is exactly the amalgam that the hormone optimization discourse exploits: it joins low vitamin D, borderline testosterone and a thyroid at the frontier into a single narrative of collapse, when they are separate stories and, almost always, benign ones.

Management follows from the reasoning. Faced with multiple deficiencies, always measure the pair, the target gland's hormone plus the trophic, and interpret the inappropriate normal. If the pattern is central, investigate the pituitary with MRI and dynamic tests when indicated, and look for the cause. If it is primary, the target is each gland and the trigger is usually age or autoimmunity, not a sellar lesion.

And there is a safety rule that justifies all the care with classification: when ACTH deficiency exists, the glucocorticoid is replaced before levothyroxine. Starting the thyroid first accelerates the metabolism of the little cortisol available and can precipitate an adrenal crisis (Fleseriu et al., 2016). The cortisol axis is the one that kills, and it is the one protected first. Recognizing that the picture is central, and not a sum of primary failures, is what triggers this precaution.

The anti-fad counterpoint closes the text. One should not call the hormonal decline of age panhypopituitarism, nor nutritional vitamin D, nor treat the somatopause as if it were GH deficiency. Naming correctly is not semantic preciousness: it defines the workup, the order of replacement and the boundary between replacing what is missing and optimizing what does not need it.